Volume 19, Issue 8, Pages (August 2011)

Slides:



Advertisements
Similar presentations
Volume 342, Issue 1, Pages (January 2014)
Advertisements

Inhibition of SOX17 by MicroRNA 141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer  Yan Jia, Yunsheng Yang, Qimin Zhan, Malcolm.
MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of Breast Cancer Cells by Targeting Sex-Determining Region Y-Box 2 Cell.
Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma  Kuang-Tzu Huang, I-Ying Kuo, Ming-Chao.
Mira Park, Ph. D. , Dae-Shik Suh, M. D. , Kangseok Lee, Ph. D
Volume 145, Issue 2, Pages (August 2013)
Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria  Dan Wang, Chunsun Dai, Yingjian Li, Youhua.
DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression in Lung Cancer  Yi-Chieh Yang, MS, Yen-An Tang,
MicroRNA-31 Promotes Skin Wound Healing by Enhancing Keratinocyte Proliferation and Migration  Dongqing Li, X.I. Li, Aoxue Wang, Florian Meisgen, Andor.
Sp1 Suppresses miR-3178 to Promote the Metastasis Invasion Cascade via Upregulation of TRIOBP  Hui Wang, Kai Li, Yu Mei, Xuemei Huang, Zhenglin Li, Qingzhu.
MiR-29 Regulates Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa  Michael Vanden Oever, Daniel Muldoon, Wendy Mathews, Ron McElmurry, Jakub.
Volume 137, Issue 2, Pages e2 (August 2009)
MicroRNA-489 Plays an Anti-Metastatic Role in Human Hepatocellular Carcinoma by Targeting Matrix Metalloproteinase-7  Yixiong Lin, Jianjun Liu, Yuqi Huang,
Therapeutic Suppression of miR-4261 Attenuates Colorectal Cancer by Targeting MCC  Guanming Jiao, Qi Huang, Muren Hu, Xuchun Liang, Fuchen Li, Chunling.
Hydrogen Sulfide Demonstrates Promising Antitumor Efficacy in Gastric Carcinoma by Targeting MGAT5  Rui Wang, Qilin Fan, Junjie Zhang, Xunan Zhang, Yuqi.
PTF1α/p48 and cell proliferation
Volume 19, Issue 12, Pages (December 2017)
Volume 136, Issue 2, Pages (February 2009)
Volume 12, Issue 3, Pages (July 2015)
Volume 19, Issue 3, Pages (March 2017)
Volume 21, Issue 6, Pages (June 2013)
Volume 20, Issue 2, Pages (February 2018)
Volume 19, Issue 2, Pages (February 2011)
Uc.454 Inhibited Growth by Targeting Heat Shock Protein Family A Member 12B in Non- Small-Cell Lung Cancer  Jun Zhou, Chenghai Wang, Weijuan Gong, Yandan.
Volume 152, Issue 1, Pages (January 2019)
Volume 22, Issue 10, Pages (October 2014)
Molecular Therapy - Nucleic Acids
Volume 145, Issue 2, Pages (August 2013)
Volume 25, Issue 3, Pages (March 2017)
MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2  Ji-guang Zhang,
Volume 24, Issue 5, Pages (May 2016)
Volume 25, Issue 9, Pages (September 2017)
Volume 142, Issue 7, Pages e2 (June 2012)
Volume 84, Issue 2, Pages (August 2013)
Volume 22, Issue 2, Pages (February 2014)
Volume 23, Issue 10, Pages (October 2015)
Volume 137, Issue 6, Pages (June 2009)
TGFβ/SMAD/microRNA-486-3p Signaling Axis Mediates Keratin 17 Expression and Keratinocyte Hyperproliferation in Psoriasis  Man Jiang, Zhongbin Sun, Erle.
Integrative Functional Genomics Implicates EPB41 Dysregulation in Hepatocellular Carcinoma Risk  Xinyu Yang, Dianke Yu, Yanli Ren, Jinyu Wei, Wenting.
MiR-125b, a MicroRNA Downregulated in Psoriasis, Modulates Keratinocyte Proliferation by Targeting FGFR2  Ning Xu, Petter Brodin, Tianling Wei, Florian.
MiR-135b Stimulates Osteosarcoma Recurrence and Lung Metastasis via Notch and Wnt/β-Catenin Signaling  Hua Jin, Song Luo, Yun Wang, Chang Liu, Zhenghao.
Volume 23, Issue 1, Pages (January 2015)
Volume 23, Issue 7, Pages (July 2015)
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
Molecular Therapy - Nucleic Acids
Inhibition of SOX17 by MicroRNA 141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer  Yan Jia, Yunsheng Yang, Qimin Zhan, Malcolm.
Promotion Effects of miR-375 on the Osteogenic Differentiation of Human Adipose- Derived Mesenchymal Stem Cells  Si Chen, Yunfei Zheng, Shan Zhang, Lingfei.
Lu Zheng, Nan You, Xiaobing Huang, Huiying Gu, Ke Wu, Na Mi, Jing Li 
Kun-Peng Zhu, Xiao-Long Ma, Chun-Lin Zhang  Molecular Therapy 
Molecular Therapy - Nucleic Acids
Volume 17, Issue 2, Pages (February 2009)
Volume 25, Issue 4, Pages (April 2017)
Shrimp miR-34 from Shrimp Stress Response to Virus Infection Suppresses Tumorigenesis of Breast Cancer  Yalei Cui, Xiaoyuan Yang, Xiaobo Zhang  Molecular.
Volume 26, Issue 8, Pages (August 2018)
Molecular Therapy - Nucleic Acids
Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504
Volume 6, Issue 3, Pages (March 2016)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
The lncRNA PDIA3P Interacts with miR-185-5p to Modulate Oral Squamous Cell Carcinoma Progression by Targeting Cyclin D2  Cheng-Cao Sun, Ling Zhang, Guang.
Molecular Therapy - Nucleic Acids
miR-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice
Volume 22, Issue 6, Pages (June 2014)
Molecular Therapy - Nucleic Acids
Volume 22, Issue 9, Pages (September 2014)
Volume 21, Issue 2, Pages (February 2013)
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI  Feng Xing, Shuo Wang, Jianhong Zhou  Molecular.
Volume 24, Issue 10, Pages (October 2016)
Volume 26, Issue 9, Pages (September 2018)
Volume 23, Issue 4, Pages (April 2015)
Presentation transcript:

Volume 19, Issue 8, Pages 1521-1528 (August 2011) Tumor-specific Expression of MicroRNA-26a Suppresses Human Hepatocellular Carcinoma Growth via Cyclin-dependent and -independent Pathways  Lizao Chen, Jianming Zheng, Yan Zhang, Luxi Yang, Jiaqi Wang, Jian Ni, Daxiang Cui, Chaoqin Yu, Zailong Cai  Molecular Therapy  Volume 19, Issue 8, Pages 1521-1528 (August 2011) DOI: 10.1038/mt.2011.64 Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 MicroRNA-26a (mir-26a) negatively regulates normal liver cell proliferation, and specific expression of miR-26a specifically suppresses tumor cell proliferation. (a) Real-time PCR detected the expression of mature miR-26a in L02 cells transfected with ph1MCG or its control vector ph1CG (normalized to U6 levels). (b) Compared with the control vector ph1CG, overexpression of miR-26a negatively regulated cell proliferation. (c) In the ph1MCG group, the percentage of cells in the G1 phase of the cell cycle increased by ∼20%. Accordingly, cell growth was reduced significantly. (d) Expression of mature miR-26a was detected by real-time PCR in Huh-7, SMMC-7721, and L02 cells transfected with pAT, pTM, pAM, and pATM. Relative expression was normalized to U6 levels. (e) Growth of Huh-7, SMMC-7721, and L02 cells after transfection with the indicated plasmids. The growth index was assessed at 0, 1, 2, 3, and 4 days. (f) Western blot analysis of cyclin D2 and cyclin E2 in Huh-7, SMMC-7721, and L02 cells transfected with pAT, pAM, pTM, and pATM. β-Actin served as an internal control. *P < 0.05, **P < 0.01. Molecular Therapy 2011 19, 1521-1528DOI: (10.1038/mt.2011.64) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 MicroRNA-26a (miR-26a) targets ERS1, and expression of estrogen receptor-α (ERα) and miR-26a in patient hepatocellular carcinoma (HCC) tissues (T) and pair-matched adjacent tissues (N) n = 12. (a) Western blot analysis demonstrates an abundance of ERα in pATM-transfected Huh-7 cells. The band intensities were normalized to β-actin levels. (b) Dual luciferase assay of Huh-7 cells co-transfected with the firefly luciferase constructs containing the ESR1 WT or Mut 3′-UTR and miR-26a mimics or scrambled oligonucleotides as the negative control. (c) Sequence and evolutionary conservation of the miR-26a binding site in the 3′-UTRs of transcripts encoding ERα (ESR1). The interaction sites between WT and Mut 3′-UTRs of ESR1 and miR-26a are indicated. (d) Western blot analysis of ERα protein in human HCC. β-Actin serves as an internal control (gray scale is represented as the mean ± SD). Expression of (e) mature miR-26a and (f) ESR1 was detected by real-time PCR. Relative expression was normalized to U6 and β-actin levels, respectively. *P < 0.05, **P < 0.01. Molecular Therapy 2011 19, 1521-1528DOI: (10.1038/mt.2011.64) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 MicroRNA-26a (miR-26a) downregulates the expression of estrogen receptor-α (ERα) and partly blocks the E2-ERα pathway. (a) Growth curve of Huh-7 cells treated with different concentrations of E2 at 0, 1, 2, and 3 days. (b) Proliferation index of Huh-7 cells stably transfected with or without pATM as well as transient transfected with pcDNA3.1-ERα/pcDNA3.1 and treated with E2 or Fulvestrant on day 2. (c) Immunofluorescence assay of Huh-7 cells stably transfected with or without pATM and treated with E2 or Fulvestrant at 8 hours to detect ERα expression (red) in the cell nucleus. DAPI (blue) was used to stain the nuclei. *P < 0.05, **P < 0.01. Molecular Therapy 2011 19, 1521-1528DOI: (10.1038/mt.2011.64) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 MicroRNA-26a (miR-26a) driven by the human α-fetoprotein (hAFP) and human telomerase reverse transcriptase (hTERT) dual promoter inhibits tumor cell growth in vivo. (a) Nude mice were inoculated with pATM- or pAT-transfected Huh-7 cells in their flanks. Two of the five mice are shown here. (b) Representative tumor growth 5 weeks after inoculation. Tumor volume was calculated. Data are represented as the mean ± SD. n = 5. (c) Expression of estrogen receptor-α (ERα) was measured by immunohistochemistry in the tissues of mice inoculated with pATM- or pAT-transfected Huh-7 cells. (d) Hematoxylin-eosin (HE) staining of tumor sections demonstrates the character of the hepatocellular carcinoma (HCC)-bearing nude mouse model generated by inoculation with HCC cell lines (×200). Molecular Therapy 2011 19, 1521-1528DOI: (10.1038/mt.2011.64) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Specific expression of microRNA-26a (miR-26a) for therapeutic experiments. (a) Tumor growth was observed in nude mice whose tumors were treated with the pATM or pAT mixture. (b) Hematoxylin-eosin (HE) staining of the hepatocellular carcinoma (HCC) mouse model SMMC-LTNM, which more closely models the clinical character of HCC (×200). (c) Representative tumor suppression 4 weeks after treatment. Tumor volume was calculated. Data are represented as the mean ± SD. n = 5. Molecular Therapy 2011 19, 1521-1528DOI: (10.1038/mt.2011.64) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Immunohistochemistry assay of tumor tissues treated with the pATM or pAT mixture, respectively. Proteins were divided into five groups: (a) tumor marker [α-fetoprotein (AFP) and CEA]; (b) cyclin-dependent pathway (cyclin D2 and cyclin E2); (c) cyclin-independent pathway [estrogen receptor-α (ERα), PR, and P53]; (d) proliferation index (PCNA and Ki-67) and (e) antioncogene (P53 and PTEN). The brown color seen in the cells denotes positive staining for the aforementioned proteins. The white frame indicates a representative ×400 magnification field. The original magnification is ×200. (f) Quantitative analysis of PCNA- and Ki-67-positive cells in each group. *P < 0.05. Molecular Therapy 2011 19, 1521-1528DOI: (10.1038/mt.2011.64) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions